.jpeg)
2026-04-28 03:18:38
This article provides a detailed analysis of the mechanism of action, tumor shrinkage logic, and efficacy evaluation methods of pazopanib, an anti-angiogenic targeted drug, to help patients with renal cell carcinoma and soft tissue sarcoma fully understand its therapeutic value.
2026-04-24 06:39:34
Tabrecta (Capmatinib) is an oral targeted drug designed for advanced non-small cell lung cancer (NSCLC) with METex14 skipping mutations. By inhibiting aberrant MET protein, it offers tumor shrinkage and prolonged response, alongside manageable side effects.
2026-04-23 05:36:07
Study reveals pazopanib’s potential in cutaneous angiosarcoma, offering improved survival and manageable safety despite not meeting PFS endpoint.
2026-04-22 07:26:16
As a bispecific T cell engager, Tarlatamab revolutionizes cancer treatment by activating immune attacks. This guide outlines unique immune-related adverse events (irAEs) and global management strategies.
2026-04-22 07:18:24
As a 3rd-generation EGFR-targeted therapy, Almonertinib offers significant benefits for NSCLC, but safety management—focused on lung toxicity, skin reactions, cardiac risks, and drug interactions—is crucial for long-term use.
2026-04-21 04:14:58
This article specifies home storage requirements for the oral HSP90 inhibitor Pimitespib, covering temperature, humidity and light protection to maintain drug stability and efficacy, supporting long-term medication management.
2026-04-21 02:29:17
Cemiplimab (brand name Libtayo) is a fully human PD-1 immune checkpoint inhibitor developed by Regeneron Pharmaceuticals. Approved by the U.S. FDA in September 2018, it was the first breakthrough therapy for metastatic or locally advanced cutaneous squamous cell carcinoma. By blocking PD-1 ligand binding to activate T-cell anti-tumor activity, it is now approved for the treatment of multiple cancers including cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer.
2026-04-20 03:57:16
Mirvetuximab soravtansine (brand name Elahere) is the world's first folate receptor alpha (FRα)-targeted antibody-drug conjugate (ADC) developed by ImmunoGen, USA. It has received full approval from the FDA, EMA, and other global regulatory agencies for the treatment of adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
2026-04-15 05:07:26
Mitotane, the sole approved drug for adrenocortical carcinoma (ACC), is reaffirmed as the preferred adjuvant therapy in the latest NCCN Guidelines 2026. This article dissects its mechanisms, dosing protocols, safety considerations, and international pricing trends, offering authoritative guidance for Hong Kong, Macau, and overseas patients.
2026-04-13 06:40:50
Trodelvy is a breakthrough antibody-drug conjugate (ADC) targeting Trop-2, approved for metastatic triple-negative breast cancer (mTNBC), urothelial carcinoma, and other Trop-2 positive solid tumors. Learn about its mechanism, indications, safety, and global accessibility.
2026-04-10 05:05:56
Ibrutinib, a BTK inhibitor, targets mantle cell lymphoma, chronic lymphocytic leukemia, and other blood cancers by blocking the B-cell receptor pathway. Monotherapy or combination regimens improve outcomes, while managing risks such as bleeding and infections.
2026-04-10 04:56:03
Axitinib, a targeted therapy, demonstrates significant efficacy in advanced renal cell carcinoma (RCC). Combining with immunotherapy or as monotherapy, it offers innovative first-line and second-line treatment approaches, effectively prolonging survival and improving quality of life while managing potential side effects.
